The experiment involves drugs. | The observed indicators. | research results |
Canagliflozin | IHTG, HbA1c, weight | HbA1c↓, weight↓, IHTG↓ [15] |
Dapagliflozin | BM, IHTG, Plasma amino acid concentration | BM↓, IHTG↓, There was little difference in the change of AAs among the groups. [16] |
Dapagliflozin, Canagliflozin | Liver fat content, Subcutaneous and visceral fat mass, Body fat/weight ratio, Skeletal muscle mass/weight ratio, liver enzyme | Liver fat content↓, Subcutaneous and visceral fat mass↓, Body fat/weight ratio↓, Skeletal muscle mass/weight ratio↑, liver enzyme (AST, ALT, γ-GGT) ↓ [14] |
Canagliflozin | Histological evaluation, insulin resistance, serum ferritin | After 5 years, histology showed improvements in 50%, no change in 17%, and deterioration in 33%. Scores for steatosis, lobular inflammation, ballooning, and fibrosis stages decreased by 67%, 33%, 0%, and 33% respectively. insulin resistance↓, serum ferritin↓ [26] |
Canagliflozin | Incidence of hepatocyte steatosis, BMI, waistline, fasting blood-glucose, γ-GGT, ferroprotein, Type IV Collagen 7S, Histopathological findings | Incidence of hepatocyte steatosis↓, BMI↓, waistline↓, fasting blood-glucose↓, γ-GGT↓, ferroprotein↓, Type IV Collagen 7S↓, The histopathology of the tissues improved, and there was enhancement in the results of transient elastography (liver stiffness measurement). [19] |
Empagliflozin | body mass index, Liver biopsy was repeated at the end of treatment | body mass index↓, waistline↓, systolic pressure↓, diastolic pressure↓, fasting blood-glucose↓, total cholesterol↓, γ-GGT↓, Volume liver fat fraction↓ Steatosis, ballooning and fibrosis were improved [20] |
Ipragliflozin | HbA1c, BMI | HbA1c↓, BMI↓ [21] |